Featured Publications
In the balance: No new diagnosis needed in addition to opioid use disorder to study harms associated with long‐term opioid therapy
Drexler K, Edens E, Trafton J, Compton W. In the balance: No new diagnosis needed in addition to opioid use disorder to study harms associated with long‐term opioid therapy. Addiction 2023, 119: 6-8. PMID: 37766392, DOI: 10.1111/add.16349.Peer-Reviewed Original Research
2018
Co-occurring Substance and Mental Health Disorders
Jorandby-Quinones L, Edens E, Rosenheck R. Co-occurring Substance and Mental Health Disorders. 2018, 307-333. DOI: 10.1007/978-1-4939-7438-2_20.ChaptersDual diagnosisMental health care deliveryHigh treatment burdenMore medical conditionsMental health care systemMental health disordersSubstance use disordersCo-occurring substanceEvolution of treatmentHealthcare delivery approachHealth care deliveryHealth care systemTreatment burdenMedical conditionsUse disordersHealth disordersMedical carePatientsCare deliveryPsychosocial conditionsIndividual diseasesCare systemDiagnosisTreatmentDisease
2013
Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence
Ralevski E, Jane J, O’Brien E, Edens E, Arnaout B, Kerfoot K, Keegan K, Weiner J, Russo M, Petrakis I. Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence. Journal Of Dual Diagnosis 2013, 9: 301-310. DOI: 10.1080/15504263.2013.835163.Peer-Reviewed Original ResearchDepressive symptomsAlcohol dependenceDual diagnosisRates of smokingMain outcome variablesSymptoms of depressionTreatment of peopleTreatment trialsComorbid depressionMecamylamineSide effectsNonsmokersSmokingSymptomsOutcome variablesBest treatmentDrinking outcomesDepressionPlaceboSmokersFurther studiesSignificant differencesDiagnosisParticipantsTreatment